Biotech start-up RNATICS strengthens its management team with Prof. Dr. Thomas Thum. As an internationally recognized expert in the field of RNA medicine, he will provide the company with strategic and scientific support. RNATICS is part of BioM's MAxL start-up incubator and develops innovative RNA therapeutics against inflammatory lung diseases.
The Martinsried-based biotech start-up RNATICS has appointed Prof. Dr. Thomas Thum to its Board of Directors. With more than 20 years of experience in the field of RNA therapeutics and as co-founder of Cardior Pharmaceuticals GmbH, Thum has made a significant contribution to the development of innovative RNA-based approaches. In addition to his role as Director of the Institute for Molecular and Translational Therapeutic Strategies (IMTTS) at the Hannover Medical School, his research focuses on the role of microRNAs in tissue regeneration and repair.
RNATICS develops targeted nucleic acid therapies against disease-causing RNAs in macrophages. The proprietary technology is based on an innovative carbohydrate-coupling technology that enables the targeted delivery of RNA therapeutics to lung macrophages. This approach opens up new possibilities for the treatment of various inflammatory lung diseases.
“This cell-specific targeting is a game changer for the treatment of inflammatory lung diseases,” said Dr. Johannes Schmidt, CEO of RNATICS. “We are pleased to welcome Prof. Thum’s expertise as we advance our lead candidate, RCS-21, and further expand the application potential of our RNA delivery platform.”